Semaglutide mildly suppresses bone remodeling in healthy and chronic kidney disease rats at weight-loss doses.

Chronic kidney disease (CKD) significantly impairs bone health, leading to CKD-mineral and bone disorder (CKD-MBD), characterized by abnormal bone turnover, mineralization, and volume. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide are widely used for their metabolic benefits, including weight loss and glycemic control. However, the long-term effects of GLP-1RA treatment on skeletal integrity, particularly in vulnerable populations such as those with CKD, remain largely undefined. Understanding semaglutide's impact on bone structure and remodeling is crucial to inform clinical practice and ensure comprehensive patient care.

Researchers investigated semaglutide's effects on bone in male Cy/+IU rats, a model for progressive CKD, alongside healthy littermate controls. Animals received semaglutide at escalating doses for a duration of 28 days. Key endpoints included assessment of bone structure using micro-CT, evaluation of bone remodeling through histomorphometry, and determination of bone mechanical properties via 3-point bending tests. This design aimed to capture both structural and functional changes in the skeletal system under semaglutide treatment.

Semaglutide treatment consistently led to reduced food intake and subsequent body weight loss across both healthy and CKD rat groups. > Notably, CKD rats receiving semaglutide exhibited 15% lower body weight at the study endpoint compared to controls. The study also observed a mild suppression of bone remodeling in both healthy control rats and those with chronic kidney disease. While the abstract indicates this suppression, specific quantitative data on bone formation or resorption markers, or changes in bone mechanical properties, were not detailed beyond the general finding of "mild suppression." No specific p-values or statistical significance metrics were provided for the bone remodeling changes.